7
BioByte 074: Why Mars is tough for life, an autoantibody signature for MS, selective compartmentalization for proteins, AI-designed CRISPR, RNAi-based drug design
www.decodingbio.com
Recent posts
6
BioByte 073: citizen science for DNA sequence alignment, cellular niches, updates in AI antibody design, polarizing biotech investment trends
www.decodingbio.com
9
BioByte 070: NeuroAI, proteome-scale screening of protein degraders, open source biomedical LLMs, engineering better mRNA therapeutics
www.decodingbio.com
7
BioByte 069: AI learns the meaning of life, the dysfunctome, a $400M launch for inflammatory drugs, Nvidia's 'woodstock' and engineering crops to save the planet
www.decodingbio.com
4
BioByte 068: Cell therapy for solid tumors, using a monoclonal for allergy, improving AlphaFold2 performance, using ML to understand small RNA secretion, Insilico's development of a TNIK inhibitor
www.decodingbio.com
6
BioByte 067: DNA foundation models, neural multi-task learning for drug design, non-invasive methods for brain amyloid clearance, clinical trial architectures for precision medicine
www.decodingbio.com
4
BioByte 066: CAR-T for MS, will AI replace animal testing, diagnosis of ultra-rare monogenic disorders, BigRNA: a foundation model for RNA biology, Matter Neuro raises $26M to “cure unhappiness"
www.decodingbio.com
long-read
15
Scaling Biology 001: Chris Gibson, Co-Founder and CEO of Recursion Pharmaceuticals
www.decodingbio.com
Decoding Bio
www.decodingbio.com